Shots:
- The P-II/III TeenCOVE study involves assessing mRNA-1273 (two 100 µg doses) vs PBO in 3700+ participants in a ratio (2:1) aged 12 to <18yrs. in the US
- The study met its 1EPs i.e non-inferior immunogenicity and demonstrated 93% efficacy in seronegative participants after 14 days following the first dose, was generally well tolerated with a safety and tolerability profile generally consistent with the P-III COVE study in adults
- Additionally, no cases of COVID-19 were seen in participants who had received both doses, consistent with a vaccine efficacy of 100%. The data will be submitted to regulators globally in early Jun’2021
Click here to read full press release/ article | Ref: Moderna | Image: STAT News
The post Moderna’s mRNA-1273 Meets its Primary Endpoint in P-II/III TeenCOVE Study to Prevent COVID 19 in Adolescents first appeared on PharmaShots.
